Compound Notes 4 min read
GLP-Class Compounds: A Clinical Timeline of When Results Actually Show
A clinical-tone timeline of what the published Phase 3 trials actually show across the GLP-class research compound family, week by week, and where the trial endpoints sit relative to when researchers ask the timeline question.
Last reviewed: May 2026
The most-asked question about GLP-class research compounds is timeline. When does anything happen? The answer the published literature supports is more specific than the marketing version, and it is worth knowing precisely if you are running a research-context protocol.
For compliance reasons we refer to the three lines by codename: SG (the GLP-1 receptor agonist line), MNJ (the dual GLP-1 + GIP line), and RT (the triple receptor agonist line). The clinical-trial data referenced below is published under the licensed-medicine names of these compounds. The research-grade versions catalogued on this site are different products in a different regulatory category. The timeline patterns hold across both because the underlying pharmacology is the same.
Week 1 to 2
Appetite begins to shift. The mechanism is direct: GLP-1 receptor agonism slows gastric emptying and signals satiety in central pathways. Subjective effects show up early. Most participants in the published trials report reduced food cues within the first two weeks. The metabolic markers have not yet moved meaningfully. Body weight may shift by 0.5 to 1 kg, mostly water and reduced caloric intake.
Week 3 to 8
The titration period. All three GLP-class lines use a graduated dose schedule designed to minimise GI side effects (nausea, slower digestion, occasional constipation). Most published trial protocols increase the dose every 4 weeks during this period. Body-composition shifts begin to be measurable. By week 8, average weight loss in trial cohorts ranges from 3 to 6% of baseline body weight, with meaningful between-individual variability.
Side effects peak in this window. The published nausea profile is highest during dose escalation and tends to attenuate as the body adapts. Researchers who report severe persistent GI effects after week 8 may be at a dose ceiling for their individual tolerance.
Week 8 to 24
The body of the response curve. Weight loss accelerates in most participants and then begins to plateau toward the end of this window. The Phase 3 SURMOUNT-1 trial of MNJ at 15 mg showed an average 22.5% reduction in body weight at 72 weeks, with the steepest portion of the curve falling in the week 12 to 36 range. STEP-1, the Phase 3 trial of SG at 2.4 mg, showed an average 14.9% reduction at 68 weeks, with similar curve shape. RT trial data at 12 mg has shown the largest average effect of the three lines, in the 24% range over 48 weeks.
Note: those trial figures are for the licensed medicines under medical supervision. Research-context use of the equivalent compounds sits in a different regulatory and clinical category. Phase 3 trial data is the cleanest available reference for the kinetic shape, not a prediction of what any individual will experience.
Week 24 to 48
The plateau region. Weight loss continues for most participants but at a reduced rate. Body composition shifts become more visible (the loss of fat mass becomes more pronounced relative to weight). Some participants reach a maintenance steady-state. Others continue gradual loss at the same dose.
The metabolic markers move in this window. HbA1c (a 3-month glucose-control marker) typically improves by 1 to 2 percentage points in cohorts with elevated baseline. Lipid profile shifts are variable but generally favourable. Cardiovascular markers (resting heart rate, blood pressure) tend to follow the body-composition curve.
Week 48 to 68 and beyond
The endpoint of most published Phase 3 trials. The compound has done most of what it is going to do. Continued use sustains the new body-composition steady-state. Discontinuation, the trial data is consistent on this, leads to substantial regression toward baseline within the following 12 to 24 months in most cohorts. The mechanism does not produce a permanent metabolic shift in the absence of continued signalling.
Where the timeline diverges by line
SG (the GLP-1 monotherapy line) has the longest clinical track record and the most-studied response curve. Onset is consistent. Effect size is moderate. Side-effect profile is well-characterised.
MNJ (the dual GLP-1 + GIP line) shows steeper early-window response and a larger total effect. Side-effect profile is broadly similar to SG, with the GIP component possibly contributing to slightly different appetite mechanics.
RT (the triple receptor agonist line) shows the steepest response curve and the largest absolute effect in the available trial data. The trade-off is more aggressive titration requirements and a slightly higher rate of GI side effects in the published data.
What the timeline implies for protocol design
A 12-week protocol does not capture the response curve. It captures the titration window. Researchers who run 12-week protocols are seeing the early portion of the effect, not the body of it. The Phase 3 trial protocols ran 68 weeks for a reason.
The supplement layer that supports active GLP-class protocols matters more than most marketing implies. Reduced caloric intake leads to under-consumption of sodium, potassium, and protein. Hydra Core covers the electrolyte profile. Adequate dietary protein at the higher end of the research-supported range (1.6 to 2.2 g/kg per day) preserves lean mass during the body-composition shift. Our protein synthesis piece covers the dose math.
What NuroCore offers
The peptide catalogue includes the GLP-class research compounds under codename. The Protocol Builder Composition goal seeds a curated stack including the supplement-layer support. Our GLP buyer-questions piece addresses the most-asked specifics.
The clinical line
Whether a GLP-class research compound belongs in your specific situation, at what dose, for how long, is a clinical question that belongs with a UAE-licensed healthcare professional. The Phase 3 data is reference material, not a personalised prescription.